These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. Potential of transdermal drug delivery in Parkinson's disease. Pfeiffer RF Drugs Aging; 2002; 19(8):561-70. PubMed ID: 12207550 [TBL] [Abstract][Full Text] [Related]
70. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604 [TBL] [Abstract][Full Text] [Related]
71. Parallel double-blind study of pergolide in Parkinson's disease. Jankovic J; Orman J Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265 [No Abstract] [Full Text] [Related]
72. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. Mark MH; Sage JI Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626 [TBL] [Abstract][Full Text] [Related]
73. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. Olanow CW; Alberts MJ Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266 [No Abstract] [Full Text] [Related]
74. A double-blind evaluation of ciladopa in Parkinson's disease. Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914 [TBL] [Abstract][Full Text] [Related]